Navigation Links
Hospira Names Brian Meadows Supply Chain Chief

LAKE FOREST, Ill., April 27 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, announced today that Brian Meadows has been named corporate vice president, Supply Chain. In this capacity, he will be responsible for enterprise-wide supply chain operations including demand and supply planning; strategic sourcing and supplier management; procurement; materials and production planning; transportation management and distribution operations.

In addition, Meadows will lead the procurement effort within Project Fuel, Hospira's multi-phased initiative designed to identify and liberate resources across the organization to reduce complexity, improve efficiencies and optimize financial performance. The procurement effort will leverage Hospira's global scale to provide a sustainable advantage in the areas of productivity, cost, innovation and flexibility with the company's suppliers.

"Brian is a proven operations executive with leadership strengths in supply chain management and cost reduction," said Terrence C. Kearney, chief operating officer, Hospira. "Establishing Hospira's supply chain as a competitive advantage is a key strategic imperative, and we're excited to have Brian leading this effort."

Most recently, Meadows, 48, was senior vice president of supply chain management at Sprint-Nextel Corporation, where he led the integration of the supply chain operations of Sprint and Nextel Communications. Prior to Sprint, Meadows was the senior vice president of supply chain management at Nextel, where he centralized and built the supply chain organization. His supply chain operating experience is complemented by a consulting career in which he was a principal at A.T. Kearney and a partner at Deloitte Consulting.

Meadows earned his bachelor's degree from the University of Wisconsin-Madison in Civil and Environmental Engineering, and his master's of business management from the Kellogg School of Management at Northwestern University.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at

SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biogenerics Will Save Billions, Says Hospira CEO
2. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
3. Hospira Expands Board of Directors
4. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
5. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
6. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
7. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
8. Hospira Supports Newly Introduced Biogenerics Legislation
9. KGI Names Kerry Howell Vice President for Advancement
10. Vical Names Andrew de Guttadauro Vice President, Corporate Development
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
Breaking Biology Technology:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):